-
-
- 2020-10-10
First in China! Wanbang Biopharma Perphenazine Tablets Pass Generics Consistency Evaluation
Recently, Shanghai Zhaohui Pharmaceutical Co., Ltd. ("Zhaohui Pharmaceutical"), a member enterprise of Jiangsu Wanbang Biopharmaceuticals Co., Ltd. ("Wanbang Biopharma"), received the Notice on Approval of Supplementary Drug Application for Perphenazine Tablets (2 mg, 4 mg) (No.: 2020B04654, 2020B04655) from NMPA. The drug is the first of its kind in China to pass the consistency evaluation of quality and efficacy of generic drugs.
-
-
-
- 2020-10-09
Investigational New Drug Application of Henlius SARS-CoV-2 Neutralizing Antibody HLX70 Approved by US FDA
HLX70 is a genetically engineered fully humanized monoclonal antibody that targets the receptor-binding domain (RBD) of the S1 subunit of SARS-CoV-2 spike protein (S protein) and is a typical IgG1 Kappa immunoglobulin.
-
-
-
- 2020-09-21
Brief Product News | New Progress in Henlius Anti-HER2 Therapy! First Patient Dosed in Phase 1 Clinical Trial of Henlius Pertuzumab Biosimilar HLX11
HLX11 was independently developed by Henlius with the pertuzumab originator as reference drug and the development is in accordance with China's biosimilar guidelines.
-
-
-
- 2020-09-10
Henlius Bevacizumab Biosimilar HLX04 Receives NDA Acceptance Notification from NMPA
HLX04 was developed with the bevacizumab originator as reference product and the development process is in line with China’s biosimilar guidelines.
-